Navigation For Mobile

Category Archives: drug discovery

The Growing Impact of Rare Disease Drugs

AstraZeneca’s $39-billion acquisition of Alexion Pharmaceuticals  joined by Merck’s acquisition of Acceleron for $11.5 billion and other deals, have made the Rare Disease space a destination for Big Pharma this…

Posted in drug discovery, drugs, FDA, Orphan drug | Tagged , | Comments Off on The Growing Impact of Rare Disease Drugs

Pharma 2020-2021: Much More Than Just COVID

Set aside ‘Everything-COVID,’ and to many outsiders the past 20 months can appear as though the pharmaceutical industry took a sabbatical. Not true, of course…but everything else that occurred in…

Posted in Chemistry, COVID19, drug discovery, drugs, Industry news, R&D, supply chain | Comments Off on Pharma 2020-2021: Much More Than Just COVID

What Lessons Has Pharma Learned From COVID?

There’s an eye-popping amount of good news for pharma floating around out there. One report claims a ‘Golden decade of unbelievable innovation’ lies ahead. Others point to COVID19 as the…

Posted in Contract Manufacturing, COVID19, drug discovery, drugs, R&D, regulatory | Comments Off on What Lessons Has Pharma Learned From COVID?

Small Pharma Steps Up

Here’s some good news, courtesy of DCAT Value Chain Insights: “Smaller bio/pharmaceutical companies are accounting for an increasingly larger portion of new products as measured by recent new molecular entity…

Posted in drug discovery, drugs, FDA | Tagged , , , , | Comments Off on Small Pharma Steps Up

The Need for Speed: Drug Development, Trials & Regulatory Pathways Accelerate in the Wake of COVID-19

For drug makers, speed has always mattered. Every day a drug is delayed on the path to market costs pharma companies millions of dollars. Delays can also lead to the…

Posted in analytical science, Chemistry, COVID19, drug discovery, drugs | Tagged , , , , , , | Comments Off on The Need for Speed: Drug Development, Trials & Regulatory Pathways Accelerate in the Wake of COVID-19

Pharma Drug Innovation in 2020: From Novel Drugs to Drugs for Novel Coronavirus

Have other areas in drug discovery suffered because of COVID-19? It’s probably not too early to say that COVID-19 has changed pharmaceutical drug discovery considerably. And why wouldn’t it have,…

Posted in Chemistry, drug discovery, drugs, FDA, Neuland Labs, R&D, regulatory | Tagged , , | Comments Off on Pharma Drug Innovation in 2020: From Novel Drugs to Drugs for Novel Coronavirus

China Launches New Marketing Authorization Holder (MAH) System

In December 2019, China issued a revision to their Drug Administration Law. It was the most wide-ranging modification of their laws since 2001. It marked a fundamental shift away from…

Posted in API synthesis, APIs, drug discovery, drugs, regulatory | Comments Off on China Launches New Marketing Authorization Holder (MAH) System

Alzheimer’s and Brain Awareness Month

June is Alzheimer’s and Brain Awareness Month. Alzheimer’s Disease (AD) is a heartbreaking and tragic condition affecting millions of families worldwide. This month, we highlight how health and pharma intersect….

Posted in Alzheimers, drug discovery, drugs, generic, Neuland Labs | Tagged , | Comments Off on Alzheimer’s and Brain Awareness Month

Inside QBD: Chemists & Engineers Collaborate on Quality

In a PharmTech webcast, the Neuland team linked up with Dr. San Kiang – Research Professor from the Department of Chemical Engineering at Rutgers University. The objective was a discussion…

Posted in Chemistry, drug discovery, drugs, process chemistry, Process Engineering, QbD, Quality, R&D, Route Design, Route Scouting, scale-up, Synthesis Route | Comments Off on Inside QBD: Chemists & Engineers Collaborate on Quality

Niche Growth & Growing Niches: A Market Report on APIs and Eroom’s Law

A recent market report on APIs by Future Market Insights (FMI) paints a generally rosy economic picture of the industry over the next decade, but in this case the report’s…

Posted in API synthesis, APIs, Contract Manufacturing, drug discovery, drugs, Neuland Labs, peptide, peptides, Pharm Tech, Pharmaceutical Technology | Comments Off on Niche Growth & Growing Niches: A Market Report on APIs and Eroom’s Law